Opportunity to undertake an MSc in Health Economics at the University of London

By HEOR Staff Writer

February 10, 2023

Opportunity to undertake an MSc in Health Economics at the University of London. Apply for a Fellowship Programme by 30 April 2023.

The Office of Health Economics (OHE) provides various forms of support to the upcoming generation of health economists in order to fulfil our philanthropic goals. They have established an MSc Fellowship Programme in collaboration with City, University of London, and a PhD Programme at LSE, London School of Economics and Political Science, for individuals interested in pursuing postgraduate studies in health economics.

Their objective is to ensure the continued role of health economics in high-quality, evidence-based health policy decision-making and to strengthen and advance the discipline’s future.

For further information, please visit:

Reference url

Recent Posts

Transforming Healthcare Value: Strategic Purchasing in South Africa

By João L. Carapinha

May 20, 2026

Strategic Purchasing Healthcare offers a pathway for South Africa’s healthcare system to deliver improved patient outcomes amid constrained resources, where traditional passive purchasing models relying on historical budgets or uncapped fee-for-service payments have fallen short in prioritising e...
Learning from Global Best Practices in Healthcare Pricing Regulation

By João L. Carapinha

South Africa continues to face persistent challenges in establishing sustainable healthcare pricing regulation mechanisms, as highlighted in the keynote address at the CMS Industry Indaba. Countries including the United Kingdom, Japan, South Korea, and Thailand have implemented structured price-s...
PSA Response Improvement: Promising Data from Pluvicto in mHSPC Treatment

By João L. Carapinha

May 19, 2026

New data from the PSMAddition study indicate that Pluvicto combined with standard of care, consisting of an androgen receptor pathway inhibitor plus androgen deprivation therapy, produced a 58% lower risk of prostate-specific antigen progression compared with standard of care alone. Patients rece...